Replies to post #211230 on Cytodyn Inc (CYDY)

[Monroe1]

Here's the market wizards. The marketed killer junk that failed miserably in trials for Ebola, so bad were all the deaths the host ended the study, then made it iSOC for hospitals treating Covid. That is market wizardy forced on a duped public. However, now the cat is out of the bag. Again, Fauci will be asked, why did you not give EUA for leronlimab when more data was available than the jab data ....still not released and wanting to hide it for 75 more years from public scrutiny.

Yes, that wizardy at the FDA who just recently blocked a known dietary substance shown in multiple studies to be highly effective,,,and of course, we know about the FDA never done before hit letter unsigned that so wizardly worded that subgroups were not important....all to cover their ass for not allowing dosing over the course of the month as requested. Yes, here it is and now the piper will be paid as this continues to go forward. Then maybe leronlimab will have it's covid moment history.

Till then we got NASH and a host of others coming on... so listen up intently in a couple of hours. Expect good things! $CYDY$ Love wizardry? Here is what we are dealing with.... slight of hand, bait and switch, miscreant deeds, all on par for a long history of conniving to promote Big Pharma .... RICO anyone? It applies here: https://www.redvoicemedia.com/2022/06/dr-david-martin-calls-for-prosecutions-fauci-knew-remdesivir-would-kill-thousands/ Given the choice, would you take remdesivir or leronlimab? $CYDY$ turning the page to the next chapter.

TODAY TUNE IN to news!! CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Director of Research & Development, will host an investment community webcast to provide a quarterly Company update on Thursday, June 30, 2022.

Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.
Date: Thursday, June 30, 2022
Time: 1:00 pm PT / 4:00 pm ET
Access: https://event.choruscall.com/mediaframe/webcast.html?webcastid=3aO9FH10
Questions: Prior to the webcast, questions can be submitted online to [e-mail]

This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until July 30, 2022.